Industry Research Reports
Home > Reports > Medical Care > Global Oncolytic Virus Therapy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
Global Oncolytic Virus Therapy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
Industry: Medical Care
Published Date: 2025-03-28
Pages: 135 Pages
Report ld: 4673965
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Oncolytic Virus Therapy Market Size(US$)
CAGR 2025-2031
24.9%
Market Size,2031
USD 43.3
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 11.4 million
Market Forecast in 2031(Value)
US$ 43.3 million
CAGR
24.9%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
In 2024, the global market size of Oncolytic Virus Therapy was estimated to be worth US$ 9.3 million and is forecast to reach approximately US$ 43.3 million by 2031 with a CAGR of 24.9% during the forecast period 2025-2031.
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Amgen, Colytics Biotech, Iralytics and Ransgene SA are the leading providers of oncolytic virus therapy, with the first 3 accounting for about 60% of the market.
North America and Europe are the main markets, each accounting for about 40% of the market.
MARKET SEGMENTATION
By Company
- Amgen
- Oncolytics Biotech
- Viralytics
- Transgene SA
- Oncolys BioPharma
- Targovax
- PsiOxus Therapeutics
- SillaJen Biotherapeutics
- Sorrento Therapeutics
- Lokon Pharma
- Genelux Corporation
- Vyriad
- TILT Biotherapeutics
- Cold Genesys
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- HSV-based Oncolytic Viruses
- Adenoviruses-based Oncolytic Viruses
- Vaccinia Virus-based Oncolytic Viruses
- Vesicular Stomatitis Virus-based Oncolytic Viruses
- Newcastle Disease Virus-based Oncolytic Viruses
Segment by Application
- Melanoma
- Prostate Cancer
- Breast Cancer
- Ovarian Cancer
- Others
REPORT SCOPE
This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus Therapy.
The Oncolytic Virus Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oncolytic Virus Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncolytic Virus Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Oncolytic Virus Therapy in global and regional level.
Chapter 3: Detailed analysis of Oncolytic Virus Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncolytic Virus Therapy revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Oncolytic Virus Therapy Product Introduction
1.2 Market by Type
1.2.1 Global Oncolytic Virus Therapy Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 HSV-based Oncolytic Viruses
1.2.3 Adenoviruses-based Oncolytic Viruses
1.2.4 Vaccinia Virus-based Oncolytic Viruses
1.2.5 Vesicular Stomatitis Virus-based Oncolytic Viruses
1.2.6 Newcastle Disease Virus-based Oncolytic Viruses
1.3 Market by Application
1.3.1 Global Oncolytic Virus Therapy Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Melanoma
1.3.3 Prostate Cancer
1.3.4 Breast Cancer
1.3.5 Ovarian Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oncolytic Virus Therapy Market Size Estimates and Forecasts
2.2 Oncolytic Virus Therapy Market Size by Region: 2024 Versus 2031
2.2.1 Global Oncolytic Virus Therapy Revenue by Region: 2020-2025
2.2.2 Global Oncolytic Virus Therapy Revenue Forecast by Region (2026-2031)
2.2.3 Global Oncolytic Virus Therapy Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Oncolytic Virus Therapy Revenue by Type (2020-2031)
3.1.2 Global Oncolytic Virus Therapy Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Oncolytic Virus Therapy Revenue by Application (2020-2031)
3.2.2 Global Oncolytic Virus Therapy Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 HSV-based Oncolytic Viruses of Oncolytic Virus Therapy Revenue Market Share by Application
3.3.2 Adenoviruses-based Oncolytic Viruses of Oncolytic Virus Therapy Revenue Market Share by Application
3.3.3 Vaccinia Virus-based Oncolytic Viruses of Oncolytic Virus Therapy Revenue Market Share by Application
3.3.4 Vesicular Stomatitis Virus-based Oncolytic Viruses of Oncolytic Virus Therapy Revenue Market Share by Application
3.3.5 Newcastle Disease Virus-based Oncolytic Viruses of Oncolytic Virus Therapy Revenue Market Share by Application
4 Global Oncolytic Virus Therapy by Company
4.1 Global Oncolytic Virus Therapy Revenue by Company (2020-2025)
4.2 Global Oncolytic Virus Therapy Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Oncolytic Virus Therapy Companies around the World: Ranking by Revenue
4.3.2 Global Oncolytic Virus Therapy Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Oncolytic Virus Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Oncolytic Virus Therapy Companies Headquarters & Product Type
4.4.1 Global Oncolytic Virus Therapy Companies Headquarters
4.4.2 Date of International Companies Enter into Oncolytic Virus Therapy Market
4.4.3 Global Oncolytic Virus Therapy Companies Product & Service
4.4.4 HSV-based Oncolytic Viruses Revenue Market Share of Oncolytic Virus Therapy by Company
4.4.5 Adenoviruses-based Oncolytic Viruses Revenue Market Share of Oncolytic Virus Therapy by Company
4.4.6 Vaccinia Virus-based Oncolytic Viruses Revenue Market Share of Oncolytic Virus Therapy by Company
4.4.7 Vesicular Stomatitis Virus-based Oncolytic Viruses Revenue Market Share of Oncolytic Virus Therapy by Company
4.4.8 Newcastle Disease Virus-based Oncolytic Viruses Revenue Market Share of Oncolytic Virus Therapy by Company
4.5 Global Oncolytic Virus Therapy Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Amgen
5.1.1 Amgen Corporation Information
5.1.2 Amgen Description, Business Overview
5.1.3 Amgen Oncolytic Virus Therapy Products Offered
5.1.4 Amgen Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.1.5 Amgen Oncolytic Virus Therapy Revenue by Product in 2024
5.1.6 Amgen Oncolytic Virus Therapy Revenue by Application in 2024
5.1.7 Amgen Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.1.8 Amgen Recent Developments
5.2 Oncolytics Biotech
5.2.1 Oncolytics Biotech Corporation Information
5.2.2 Oncolytics Biotech Description, Business Overview
5.2.3 Oncolytics Biotech Oncolytic Virus Therapy Products Offered
5.2.4 Oncolytics Biotech Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.2.5 Oncolytics Biotech Oncolytic Virus Therapy Revenue by Product in 2024
5.2.6 Oncolytics Biotech Oncolytic Virus Therapy Revenue by Application in 2024
5.2.7 Oncolytics Biotech Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.2.8 Oncolytics Biotech Recent Developments
5.3 Viralytics
5.3.1 Viralytics Corporation Information
5.3.2 Viralytics Description, Business Overview
5.3.3 Viralytics Oncolytic Virus Therapy Products Offered
5.3.4 Viralytics Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.3.5 Viralytics Oncolytic Virus Therapy Revenue by Product in 2024
5.3.6 Viralytics Oncolytic Virus Therapy Revenue by Application in 2024
5.3.7 Viralytics Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.3.8 Viralytics Recent Developments
5.4 Transgene SA
5.4.1 Transgene SA Corporation Information
5.4.2 Transgene SA Description, Business Overview
5.4.3 Transgene SA Oncolytic Virus Therapy Products Offered
5.4.4 Transgene SA Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.4.5 Transgene SA Oncolytic Virus Therapy Revenue by Product in 2024
5.4.6 Transgene SA Oncolytic Virus Therapy Revenue by Application in 2024
5.4.7 Transgene SA Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.4.8 Transgene SA Recent Developments
5.5 Oncolys BioPharma
5.5.1 Oncolys BioPharma Corporation Information
5.5.2 Oncolys BioPharma Description, Business Overview
5.5.3 Oncolys BioPharma Oncolytic Virus Therapy Products Offered
5.5.4 Oncolys BioPharma Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.5.5 Oncolys BioPharma Oncolytic Virus Therapy Revenue by Product in 2024
5.5.6 Oncolys BioPharma Oncolytic Virus Therapy Revenue by Application in 2024
5.5.7 Oncolys BioPharma Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.5.8 Oncolys BioPharma Recent Developments
5.6 Targovax
5.6.1 Targovax Corporation Information
5.6.2 Targovax Description, Business Overview
5.6.3 Targovax Oncolytic Virus Therapy Products Offered
5.6.4 Targovax Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.6.5 Targovax Oncolytic Virus Therapy Revenue by Product in 2024
5.6.6 Targovax Oncolytic Virus Therapy Revenue by Application in 2024
5.6.7 Targovax Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.6.8 Targovax Recent Developments
5.7 PsiOxus Therapeutics
5.7.1 PsiOxus Therapeutics Corporation Information
5.7.2 PsiOxus Therapeutics Description, Business Overview
5.7.3 PsiOxus Therapeutics Oncolytic Virus Therapy Products Offered
5.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.7.5 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue by Product in 2024
5.7.6 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue by Application in 2024
5.7.7 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.7.8 PsiOxus Therapeutics Recent Developments
5.8 SillaJen Biotherapeutics
5.8.1 SillaJen Biotherapeutics Corporation Information
5.8.2 SillaJen Biotherapeutics Description, Business Overview
5.8.3 SillaJen Biotherapeutics Oncolytic Virus Therapy Products Offered
5.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.8.5 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue by Product in 2024
5.8.6 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue by Application in 2024
5.8.7 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.8.8 SillaJen Biotherapeutics Recent Developments
5.9 Sorrento Therapeutics
5.9.1 Sorrento Therapeutics Corporation Information
5.9.2 Sorrento Therapeutics Description, Business Overview
5.9.3 Sorrento Therapeutics Oncolytic Virus Therapy Products Offered
5.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.9.5 Sorrento Therapeutics Oncolytic Virus Therapy Revenue by Product in 2024
5.9.6 Sorrento Therapeutics Oncolytic Virus Therapy Revenue by Application in 2024
5.9.7 Sorrento Therapeutics Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.9.8 Sorrento Therapeutics Recent Developments
5.10 Lokon Pharma
5.10.1 Lokon Pharma Corporation Information
5.10.2 Lokon Pharma Description, Business Overview
5.10.3 Lokon Pharma Oncolytic Virus Therapy Products Offered
5.10.4 Lokon Pharma Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.10.5 Lokon Pharma Oncolytic Virus Therapy Revenue by Product in 2024
5.10.6 Lokon Pharma Oncolytic Virus Therapy Revenue by Application in 2024
5.10.7 Lokon Pharma Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.10.8 Lokon Pharma Recent Developments
5.11 Genelux Corporation
5.11.1 Genelux Corporation Corporation Information
5.11.2 Genelux Corporation Description, Business Overview
5.11.3 Genelux Corporation Oncolytic Virus Therapy Products Offered
5.11.4 Genelux Corporation Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.11.5 Genelux Corporation Oncolytic Virus Therapy Revenue by Product in 2024
5.11.6 Genelux Corporation Oncolytic Virus Therapy Revenue by Application in 2024
5.11.7 Genelux Corporation Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.11.8 Genelux Corporation Recent Developments
5.12 Vyriad
5.12.1 Vyriad Corporation Information
5.12.2 Vyriad Description, Business Overview
5.12.3 Vyriad Oncolytic Virus Therapy Products Offered
5.12.4 Vyriad Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.12.5 Vyriad Oncolytic Virus Therapy Revenue by Product in 2024
5.12.6 Vyriad Oncolytic Virus Therapy Revenue by Application in 2024
5.12.7 Vyriad Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.12.8 Vyriad Recent Developments
5.13 TILT Biotherapeutics
5.13.1 TILT Biotherapeutics Corporation Information
5.13.2 TILT Biotherapeutics Description, Business Overview
5.13.3 TILT Biotherapeutics Oncolytic Virus Therapy Products Offered
5.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.13.5 TILT Biotherapeutics Oncolytic Virus Therapy Revenue by Product in 2024
5.13.6 TILT Biotherapeutics Oncolytic Virus Therapy Revenue by Application in 2024
5.13.7 TILT Biotherapeutics Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.13.8 TILT Biotherapeutics Recent Developments
5.14 Cold Genesys
5.14.1 Cold Genesys Corporation Information
5.14.2 Cold Genesys Description, Business Overview
5.14.3 Cold Genesys Oncolytic Virus Therapy Products Offered
5.14.4 Cold Genesys Oncolytic Virus Therapy Revenue and Gross Margin (2020-2025)
5.14.5 Cold Genesys Oncolytic Virus Therapy Revenue by Product in 2024
5.14.6 Cold Genesys Oncolytic Virus Therapy Revenue by Application in 2024
5.14.7 Cold Genesys Oncolytic Virus Therapy Revenue by Geographic Area in 2024
5.14.8 Cold Genesys Recent Developments
6 North America
6.1 North America Oncolytic Virus Therapy Market Size YoY Growth 2020-2031
6.2 North America Oncolytic Virus Therapy Market Facts & Figures by Country (2020-2031)
6.3 North America Oncolytic Virus Therapy Revenue by Type (2020-2025)
6.4 North America Oncolytic Virus Therapy Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Oncolytic Virus Therapy Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Oncolytic Virus Therapy Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Oncolytic Virus Therapy Revenue by Type (2020-2025)
7.4 Asia-Pacific Oncolytic Virus Therapy Revenue by Application (2020-2025)
8 Europe
8.1 Europe Oncolytic Virus Therapy Market Size YoY Growth 2020-2031
8.2 Europe Oncolytic Virus Therapy Market Facts & Figures by Country (2020-2031)
8.3 Europe Oncolytic Virus Therapy Revenue by Type (2020-2025)
8.4 Europe Oncolytic Virus Therapy Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Oncolytic Virus Therapy Market Size YoY Growth 2020-2031
9.2 Latin America Oncolytic Virus Therapy Market Facts & Figures by Country (2020-2031)
9.3 Latin America Oncolytic Virus Therapy Revenue by Type (2020-2025)
9.4 Latin America Oncolytic Virus Therapy Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Oncolytic Virus Therapy Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Oncolytic Virus Therapy Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Oncolytic Virus Therapy Revenue by Type (2020-2025)
10.4 Middle East and Africa Oncolytic Virus Therapy Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Oncolytic Virus Therapy Supply Chain Analysis
11.2 Oncolytic Virus Therapy Key Raw Materials and Upstream Suppliers
11.3 Oncolytic Virus Therapy Clients Analysis
11.4 Oncolytic Virus Therapy Sales Channel and Sales Model Analysis
11.4.1 Oncolytic Virus Therapy Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Oncolytic Virus Therapy Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Oncolytic Virus Therapy Distributors
12 Oncolytic Virus Therapy Market Dynamics
12.1 Oncolytic Virus Therapy Industry Trends
12.2 Oncolytic Virus Therapy Market Drivers
12.3 Oncolytic Virus Therapy Market Challenges
12.4 Oncolytic Virus Therapy Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Oncolytic Virus Therapy Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Oncolytic Virus Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Oncolytic Virus Therapy Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Oncolytic Virus Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Oncolytic Virus Therapy Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Oncolytic Virus Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Oncolytic Virus Therapy Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Oncolytic Virus Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Oncolytic Virus Therapy Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Oncolytic Virus Therapy Revenue by Company (2020-2025) & (US$ Million)
Table 11. Oncolytic Virus Therapy Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Oncolytic Virus Therapy Players by Revenue (US$ Million) in 2024
Table 13. Global Oncolytic Virus Therapy Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Oncolytic Virus Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Therapy as of 2024)
Table 15. Global Oncolytic Virus Therapy Companies Headquarters
Table 16. Date of International Companies Enter into Oncolytic Virus Therapy Market
Table 17. Global Oncolytic Virus Therapy Companies Product & Service
Table 18. Global Oncolytic Virus Therapy Mergers & Acquisitions, Expansion Plans
Table 19. Amgen Corporation Information
Table 20. Amgen Description and Business Overview
Table 21. Amgen Oncolytic Virus Therapy Product
Table 22. Amgen Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Amgen Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 24. Amgen Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 25. Amgen Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 26. Amgen Recent Developments
Table 27. Oncolytics Biotech Corporation Information
Table 28. Oncolytics Biotech Description and Business Overview
Table 29. Oncolytics Biotech Oncolytic Virus Therapy Product
Table 30. Oncolytics Biotech Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Oncolytics Biotech Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 32. Oncolytics Biotech Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 33. Oncolytics Biotech Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 34. Oncolytics Biotech Recent Developments
Table 35. Viralytics Corporation Information
Table 36. Viralytics Description and Business Overview
Table 37. Viralytics Oncolytic Virus Therapy Product
Table 38. Viralytics Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Viralytics Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 40. Viralytics Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 41. Viralytics Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 42. Viralytics Recent Developments
Table 43. Transgene SA Corporation Information
Table 44. Transgene SA Description and Business Overview
Table 45. Transgene SA Oncolytic Virus Therapy Product
Table 46. Transgene SA Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Transgene SA Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 48. Transgene SA Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 49. Transgene SA Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 50. Transgene SA Recent Developments
Table 51. Oncolys BioPharma Corporation Information
Table 52. Oncolys BioPharma Description and Business Overview
Table 53. Oncolys BioPharma Oncolytic Virus Therapy Product
Table 54. Oncolys BioPharma Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Oncolys BioPharma Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 56. Oncolys BioPharma Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 57. Oncolys BioPharma Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 58. Oncolys BioPharma Recent Developments
Table 59. Targovax Corporation Information
Table 60. Targovax Description and Business Overview
Table 61. Targovax Oncolytic Virus Therapy Product
Table 62. Targovax Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Targovax Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 64. Targovax Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 65. Targovax Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 66. Targovax Recent Developments
Table 67. PsiOxus Therapeutics Corporation Information
Table 68. PsiOxus Therapeutics Description and Business Overview
Table 69. PsiOxus Therapeutics Oncolytic Virus Therapy Product
Table 70. PsiOxus Therapeutics Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. PsiOxus Therapeutics Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 72. PsiOxus Therapeutics Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 73. PsiOxus Therapeutics Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 74. PsiOxus Therapeutics Recent Developments
Table 75. SillaJen Biotherapeutics Corporation Information
Table 76. SillaJen Biotherapeutics Description and Business Overview
Table 77. SillaJen Biotherapeutics Oncolytic Virus Therapy Product
Table 78. SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. SillaJen Biotherapeutics Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 80. SillaJen Biotherapeutics Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 81. SillaJen Biotherapeutics Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 82. SillaJen Biotherapeutics Recent Developments
Table 83. Sorrento Therapeutics Corporation Information
Table 84. Sorrento Therapeutics Description and Business Overview
Table 85. Sorrento Therapeutics Oncolytic Virus Therapy Product
Table 86. Sorrento Therapeutics Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Sorrento Therapeutics Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 88. Sorrento Therapeutics Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 89. Sorrento Therapeutics Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 90. Sorrento Therapeutics Recent Developments
Table 91. Lokon Pharma Corporation Information
Table 92. Lokon Pharma Description and Business Overview
Table 93. Lokon Pharma Oncolytic Virus Therapy Product
Table 94. Lokon Pharma Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Lokon Pharma Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 96. Lokon Pharma Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 97. Lokon Pharma Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 98. Lokon Pharma Recent Developments
Table 99. Genelux Corporation Corporation Information
Table 100. Genelux Corporation Description and Business Overview
Table 101. Genelux Corporation Oncolytic Virus Therapy Product
Table 102. Genelux Corporation Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Genelux Corporation Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 104. Genelux Corporation Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 105. Genelux Corporation Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 106. Genelux Corporation Recent Developments
Table 107. Vyriad Corporation Information
Table 108. Vyriad Description and Business Overview
Table 109. Vyriad Oncolytic Virus Therapy Product
Table 110. Vyriad Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Vyriad Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 112. Vyriad Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 113. Vyriad Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 114. Vyriad Recent Developments
Table 115. TILT Biotherapeutics Corporation Information
Table 116. TILT Biotherapeutics Description and Business Overview
Table 117. TILT Biotherapeutics Oncolytic Virus Therapy Product
Table 118. TILT Biotherapeutics Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. TILT Biotherapeutics Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 120. TILT Biotherapeutics Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 121. TILT Biotherapeutics Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 122. TILT Biotherapeutics Recent Developments
Table 123. Cold Genesys Corporation Information
Table 124. Cold Genesys Description and Business Overview
Table 125. Cold Genesys Oncolytic Virus Therapy Product
Table 126. Cold Genesys Oncolytic Virus Therapy Revenue (US$ Million) and Gross Margin (2020-2025)
Table 127. Cold Genesys Revenue Proportion of Oncolytic Virus Therapy by Product in 2024
Table 128. Cold Genesys Revenue Proportion of Oncolytic Virus Therapy by Application in 2024
Table 129. Cold Genesys Revenue Proportion of Oncolytic Virus Therapy by Geographic Area in 2024
Table 130. Cold Genesys Recent Developments
Table 131. North America Oncolytic Virus Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 132. North America Oncolytic Virus Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 133. North America Oncolytic Virus Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 134. North America Oncolytic Virus Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 135. Asia-Pacific Oncolytic Virus Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 136. Asia-Pacific Oncolytic Virus Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 137. Asia-Pacific Oncolytic Virus Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 138. Asia-Pacific Oncolytic Virus Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 139. Europe Oncolytic Virus Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 140. Europe Oncolytic Virus Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 141. Europe Oncolytic Virus Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 142. Europe Oncolytic Virus Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 143. Latin America Oncolytic Virus Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 144. Latin America Oncolytic Virus Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 145. Latin America Oncolytic Virus Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 146. Latin America Oncolytic Virus Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 147. Middle East and Africa Oncolytic Virus Therapy Revenue by Country (2020-2025) & (US$ Million)
Table 148. Middle East and Africa Oncolytic Virus Therapy Revenue by Country (2026-2031) & (US$ Million)
Table 149. Middle East and Africa Oncolytic Virus Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 150. Middle East and Africa Oncolytic Virus Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 151. Oncolytic Virus Therapy Key Raw Materials, Industry Status and Trend
Table 152. Oncolytic Virus Therapy Key Raw Materials and Upstream Suppliers
Table 153. Oncolytic Virus Therapy Clients Status and Trend
Table 154. Oncolytic Virus Therapy Typical Clients
Table 155. Oncolytic Virus Therapy Distributors
Table 156. Oncolytic Virus Therapy Market Trends
Table 157. Oncolytic Virus Therapy Market Drivers
Table 158. Oncolytic Virus Therapy Market Challenges
Table 159. Oncolytic Virus Therapy Market Restraints
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. Oncolytic Virus Therapy Product Picture
Figure 2. Global Oncolytic Virus Therapy Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Oncolytic Virus Therapy Revenue Market Share by Type in 2024 & 2031
Figure 4. HSV-based Oncolytic Viruses Product Picture
Figure 5. Adenoviruses-based Oncolytic Viruses Product Picture
Figure 6. Vaccinia Virus-based Oncolytic Viruses Product Picture
Figure 7. Vesicular Stomatitis Virus-based Oncolytic Viruses Product Picture
Figure 8. Newcastle Disease Virus-based Oncolytic Viruses Product Picture
Figure 9. Global Oncolytic Virus Therapy Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 10. Global Oncolytic Virus Therapy Revenue Market Share by Application in 2024 & 2031
Figure 11. Melanoma
Figure 12. Prostate Cancer
Figure 13. Breast Cancer
Figure 14. Ovarian Cancer
Figure 15. Others
Figure 16. Oncolytic Virus Therapy Report Years Considered
Figure 17. Global Oncolytic Virus Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Oncolytic Virus Therapy Market Size (2020-2031) & (US$ Million)
Figure 19. Global Oncolytic Virus Therapy Market Size Market Share by Region: 2024 Versus 2031
Figure 20. Global Oncolytic Virus Therapy Revenue Market Share by Region (2020-2031)
Figure 21. Global Oncolytic Virus Therapy Revenue Market Share Forecast by Type (2020-2031)
Figure 22. Global Oncolytic Virus Therapy Revenue Market Share Forecast by Application (2020-2031)
Figure 23. HSV-based Oncolytic Viruses of Oncolytic Virus Therapy Revenue Market Share by Application, 2024 VS 2031
Figure 24. Adenoviruses-based Oncolytic Viruses of Oncolytic Virus Therapy Revenue Market Share by Application, 2024 VS 2031
Figure 25. Vaccinia Virus-based Oncolytic Viruses of Oncolytic Virus Therapy Revenue Market Share by Application, 2024 VS 2031
Figure 26. Vesicular Stomatitis Virus-based Oncolytic Viruses of Oncolytic Virus Therapy Revenue Market Share by Application, 2024 VS 2031
Figure 27. Newcastle Disease Virus-based Oncolytic Viruses of Oncolytic Virus Therapy Revenue Market Share by Application, 2024 VS 2031
Figure 28. Oncolytic Virus Therapy Revenue Share by Company (2024)
Figure 29. Oncolytic Virus Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 30. HSV-based Oncolytic Viruses Revenue Proportion by Company in 2024
Figure 31. Adenoviruses-based Oncolytic Viruses Revenue Proportion by Company in 2024
Figure 32. Vaccinia Virus-based Oncolytic Viruses Revenue Proportion by Company in 2024
Figure 33. Vesicular Stomatitis Virus-based Oncolytic Viruses Revenue Proportion by Company in 2024
Figure 34. Newcastle Disease Virus-based Oncolytic Viruses Revenue Proportion by Company in 2024
Figure 35. North America Oncolytic Virus Therapy Revenue 2020-2031 (US$ Million)
Figure 36. North America Oncolytic Virus Therapy Revenue Market Share by Type (2020-2025)
Figure 37. North America Oncolytic Virus Therapy Revenue Market Share by Application (2020-2025)
Figure 38. Asia-Pacific Oncolytic Virus Therapy Revenue 2020-2031 (US$ Million)
Figure 39. Asia-Pacific Oncolytic Virus Therapy Revenue Market Share by Region (2020-2031)
Figure 40. Asia-Pacific Oncolytic Virus Therapy Revenue Market Share by Type (2020-2025)
Figure 41. Asia-Pacific Oncolytic Virus Therapy Revenue Market Share by Application (2020-2025)
Figure 42. Europe Oncolytic Virus Therapy Revenue Growth Rate 2020-2031 (US$ Million)
Figure 43. Europe Oncolytic Virus Therapy Revenue Market Share by Country (2020-2031)
Figure 44. Europe Oncolytic Virus Therapy Revenue Market Share by Type (2020-2025)
Figure 45. Europe Oncolytic Virus Therapy Revenue Market Share by Application (2020-2025)
Figure 46. Latin America Oncolytic Virus Therapy Revenue Growth Rate 2020-2031 (US$ Million)
Figure 47. Latin America Oncolytic Virus Therapy Revenue Market Share by Country (2020-2031)
Figure 48. Latin America Oncolytic Virus Therapy Revenue Market Share by Type (2020-2025)
Figure 49. Latin America Oncolytic Virus Therapy Revenue Market Share by Application (2020-2025)
Figure 50. Middle East and Africa Oncolytic Virus Therapy Revenue Growth Rate 2020-2031 (US$ Million)
Figure 51. Middle East and Africa Oncolytic Virus Therapy Revenue Market Share by Country (2020-2031)
Figure 52. Middle East and Africa Oncolytic Virus Therapy Revenue Market Share by Type (2020-2025)
Figure 53. Middle East and Africa Oncolytic Virus Therapy Revenue Market Share by Application (2020-2025)
Figure 54. Oncolytic Virus Therapy Supply Chain (Upstream and Downstream Market)
Figure 55. Global Production Market Share of Oncolytic Virus Therapy Raw Materials by Region in 2024
Figure 56. Oncolytic Virus Therapy Distribution Channels
Figure 57. Global Oncolytic Virus Therapy Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 58. Global Oncolytic Virus Therapy Percentage 2020-2031: Online Sales VS Offline Sales
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 24.9% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
What is the annual compound growth rate of the global Oncolytic Virus Therapy market size from 2025 to 2031?
What was the global market size of Oncolytic Virus Therapy in 2025?
Which companies rank high in the global Oncolytic Virus Therapy market?
What was the global market size of Oncolytic Virus Therapy in 2031?
Related Reports
Global Oncolytic Virus Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Oncolytic Virus Therapy market size was US$ 118 million in 2025 and is forecast to reach a readjusted size of US$ 232 million by 2032 with a CAGR of 10.4% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 67
USD 4250.00
(Single User License)
Global Oncolytic Virus Therapy Market Research Report 2026
The global Oncolytic Virus Therapy market was valued at US$ 118 million in 2025 and is anticipated to reach US$ 232 million by 2032, at a CAGR of 10.4% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 99
USD 2900.00
(Single User License)
Oncolytic Virus Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Oncolytic Virus Therapy was estimated to be worth US$ 118 million in 2025 and is projected to reach US$ 232 million, growing at a CAGR of 10.4% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 73
USD 3950.00
(Single User License)
Oncolytic Virus Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Oncolytic Virus Therapy was estimated to be worth US$ 106 million in 2024 and is forecast to a readjusted size of US$ 213 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.
Published Date: 2025-10-21
Pages: 77
USD 3950.00
(Single User License)
Global Oncolytic Virus Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Oncolytic Virus Therapy market is projected to grow from US$ 106 million in 2024 to US$ 213 million by 2031, at a CAGR of 10.4% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-09-11
Pages: 103
USD 4900.00
(Single User License)
Global Oncolytic Virus Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Oncolytic Virus Therapy market size was US$ 106 million in 2024 and is forecast to a readjusted size of US$ 213 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.
Published Date: 2025-08-13
Pages: 67
USD 4250.00
(Single User License)
Global Oncolytic Virus Therapy Market Research Report 2025
The global market for Oncolytic Virus Therapy was valued at US$ 106 million in the year 2024 and is projected to reach a revised size of US$ 213 million by 2031, growing at a CAGR of 10.4% during the forecast period.
Published Date: 2025-08-13
Pages: 67
USD 2900.00
(Single User License)
Oncolytic Virus Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Oncolytic Virus Therapy was estimated to be worth US$ 9.3 million in 2024 and is forecast to a readjusted size of US$ 43.3 million by 2031 with a CAGR of 24.9% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 117
USD 3950.00
(Single User License)
Global Oncolytic Virus Therapy Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Published Date: 2024-04-17
Pages: 151
USD 5600.00
(Single User License)
Global Oncolytic Virus Therapy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Published Date: 2024-04-16
Pages: 146
USD 5900.00
(Single User License)
Global Oncolytic Virus Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Oncolytic Virus Therapy market size was US$ 118 million in 2025 and is forecast to reach a readjusted size of US$ 232 million by 2032 with a CAGR of 10.4% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 67
USD 4250.00 (Single User License)Global Oncolytic Virus Therapy Market Research Report 2026
The global Oncolytic Virus Therapy market was valued at US$ 118 million in 2025 and is anticipated to reach US$ 232 million by 2032, at a CAGR of 10.4% from 2026 to 2032.
Published: 2026-01-04
Pages: 99
USD 2900.00 (Single User License)Oncolytic Virus Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Oncolytic Virus Therapy was estimated to be worth US$ 118 million in 2025 and is projected to reach US$ 232 million, growing at a CAGR of 10.4% from 2026 to 2032.
Published: 2026-01-04
Pages: 73
USD 3950.00 (Single User License)Oncolytic Virus Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Oncolytic Virus Therapy was estimated to be worth US$ 106 million in 2024 and is forecast to a readjusted size of US$ 213 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.
Published: 2025-10-21
Pages: 77
USD 3950.00 (Single User License)Global Oncolytic Virus Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Oncolytic Virus Therapy market is projected to grow from US$ 106 million in 2024 to US$ 213 million by 2031, at a CAGR of 10.4% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-09-11
Pages: 103
USD 4900.00 (Single User License)Global Oncolytic Virus Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Oncolytic Virus Therapy market size was US$ 106 million in 2024 and is forecast to a readjusted size of US$ 213 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.
Published: 2025-08-13
Pages: 67
USD 4250.00 (Single User License)Global Oncolytic Virus Therapy Market Research Report 2025
The global market for Oncolytic Virus Therapy was valued at US$ 106 million in the year 2024 and is projected to reach a revised size of US$ 213 million by 2031, growing at a CAGR of 10.4% during the forecast period.
Published: 2025-08-13
Pages: 67
USD 2900.00 (Single User License)Oncolytic Virus Therapy- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Oncolytic Virus Therapy was estimated to be worth US$ 9.3 million in 2024 and is forecast to a readjusted size of US$ 43.3 million by 2031 with a CAGR of 24.9% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 117
USD 3950.00 (Single User License)Global Oncolytic Virus Therapy Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Published: 2024-04-17
Pages: 151
USD 5600.00 (Single User License)Global Oncolytic Virus Therapy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
Published: 2024-04-16
Pages: 146
USD 5900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 5900.00
USD 8850.00
USD 11800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
REPORT SCOPE
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now